Institute of Social and Family Medicine, School of Public Health, Zhejiang University, Hangzhou, China.
Eur J Cancer Prev. 2013 Jan;22(1):59-67. doi: 10.1097/CEJ.0b013e3283552e28.
Population-based studies on ovarian cancer providing survival estimates by age, histology, laterality, and stage have been sparse. We aimed to derive the most up-to-date and detailed survival estimates for ovarian cancer patients in Germany. We used a pooled German national dataset including data from 11 cancer registries covering 33 million populations. A total of 21 651 patients diagnosed with ovarian cancer in 1997-2006 were included. Period analysis was carried out to calculate the 5-year relative survival (RS) for the years 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Overall, the age-adjusted 5-year RS in 2002-2006 was 41%. A strong age gradient was observed, with a decrease in the 5-year RS from 67% in the age group 15-49 years to 28% in the age group 70+ years. Furthermore, the prognosis varied markedly by histology, laterality, and stage, with the age-adjusted 5-year RS ranging from 25% (for carcinoma not otherwise specified) to 81% (for stromal cell carcinoma), reaching 46% for unilateral and 32% for bilateral carcinoma and reaching 82% for Federation of Gynecology and Obstetrics (FIGO) stages I and II, 36% for FIGO stage III, and 18% for FIGO stage IV. No improvement in survival could be observed for any of the subgroups in the period between 2002 and 2006. Our analyses suggest that an improvement in the 5-year RS for ovarian cancer may have stagnated in the early 21st century and underline the need for a more effective translation of therapeutic innovation into clinical practice.
基于人群的卵巢癌研究提供了按年龄、组织学、侧别和分期划分的生存估计数据，但此类研究相对较少。本研究旨在为德国的卵巢癌患者提供最新且最详细的生存估计数据。我们使用了一个包含来自覆盖 3300 万人口的 11 个癌症登记处的数据的德国全国性数据集进行汇总分析。共纳入了 1997 年至 2006 年间诊断为卵巢癌的 21651 例患者。对 2002-2006 年期间的 5 年相对生存率（RS）进行了时期分析。使用基于模型的时期分析方法检查了 2002-2006 年期间生存率的变化趋势。使用 5 个年龄组（15-44 岁、45-54 岁、55-64 岁、65-74 岁和 75 岁以上）进行年龄调整。总体而言，2002-2006 年期间的年龄调整后 5 年 RS 为 41%。观察到明显的年龄梯度，5 年 RS 从 15-49 岁年龄组的 67%下降至 70 岁以上年龄组的 28%。此外，组织学、侧别和分期差异明显，5 年 RS 范围从非特指型腺癌的 25%（carcinoma not otherwise specified）到间质细胞瘤的 81%（stromal cell carcinoma），单侧癌为 46%，双侧癌为 32%，FIGO 分期 I 和 II 为 82%，FIGO 分期 III 为 36%，FIGO 分期 IV 为 18%。2002-2006 年期间，任何亚组的生存率均未观察到改善。我们的分析表明，卵巢癌 5 年 RS 的改善在 21 世纪初可能已经停滞不前，这凸显了将治疗创新更有效地转化为临床实践的必要性。
